ArticleESMO open2023

Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.

C Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.